Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALL

16 Mar 2021

Abstract excerpt

Abstract Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-cell acute lymphoblastic leukemia (B-ALL), which we further found to be expressed in other B-cell malignancies. Using a recently described, fully in vitro system, we selected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33727310
DOI: 10.1158/2159-8290.cd-20-0242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALLPMID 33727310Read ↗

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesSemantic proximity Read ↗

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesSemantic proximity Read ↗

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cellsSemantic proximity Read ↗

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsSemantic proximity Read ↗

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistanceSemantic proximity Read ↗

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read ↗

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read ↗

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustionSemantic proximity Read ↗

Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

A mechanistic, functional, and clinical perspective on targeting CD70 in cancerSemantic proximity Read ↗

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy targetSemantic proximity Read ↗

A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.